<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bevacizumab (Avastin(â“‡)) is a monoclonal antibody against the vascular endothelial growth factor (VEGF) receptor that increases the overall survival rate when added to standard chemotherapy regimens in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The known toxicities of bevacizumab are <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, wound healing complications, <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, <z:mp ids='MP_0001914'>bleeding</z:mp>, and gastrointestinal complications </plain></SENT>
<SENT sid="2" pm="."><plain>Especially ischemic <z:hpo ids='HP_0002583'>colitis</z:hpo> can rapidly develop into bowel <z:mpath ids='MPATH_81'>perforation</z:mpath>, so an emergency operation often is needed </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, a 65-year-old male patient developed ischemic <z:e sem="disease" ids="C0868908" disease_type="Disease or Syndrome" abbrv="">pancolitis</z:e> after FOLFOX (85 mg/m(2) <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi>, d1; 200 mg/m(2) Leucovorin, d1; 400 mg/m(2) 5-FU iv bolus, d1-2; and 600 mg/m(2) 5-FU, d1-2, every two wk) and Bevacizumab combination chemotherapy was administered </plain></SENT>
<SENT sid="4" pm="."><plain>However, he recovered after early conservative care without surgery </plain></SENT>
<SENT sid="5" pm="."><plain>We report this case with a review of literature </plain></SENT>
</text></document>